Related Experiment Video
Updated: Sep 21, 2025
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
Circulating microRNAs in patients with aneurysmal dilatation of coronary arteries
Sylwia Iwańczyk1, Tomasz Lehmann2, Artur Cieślewicz3
11st Department of Cardiology, Poznan University of Medical Sciences, 61-848 Poznań, Poland.
Insights
Researchers identified specific circulating microRNAs (miRNAs) that are differently expressed in patients with coronary artery abnormal dilatation (CAAD) compared to those with coronary artery disease (CAD) or healthy controls.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Genomics
Background:
- Coronary artery abnormal dilatation (CAAD) is a condition requiring a deeper understanding of its underlying mechanisms.
- Circulating microRNAs (miRNAs) are increasingly recognized as potential biomarkers for various cardiovascular conditions.
- Identifying specific miRNA profiles could offer insights into the pathogenesis of CAAD.
Purpose of the Study:
- To investigate and compare the expression patterns of circulating miRNAs in patients with CAAD.
- To differentiate miRNA profiles between CAAD, coronary artery disease (CAD), and healthy controls.
- To identify potential miRNA biomarkers associated with CAAD.
Main Methods:
- Plasma samples were collected from three groups: 20 patients with CAAD, 20 with CAD, and 20 healthy controls.
- MicroRNAs were isolated from plasma and profiled using PCR arrays and miRCURY LNA Serum/Plasma Focus PCR Panels.
- Statistical analysis was performed to identify significantly differentially expressed miRNAs (fold change >2, P<0.05).
Main Results:
- Significant differences in plasma miRNA levels were observed between the CAAD group and both the CAD and control groups.
- Compared to controls, 21 miRNAs were upregulated and 2 were downregulated in patients with CAAD.
- Distinct miRNA signatures were identified, with specific up- and downregulation patterns observed when comparing CAAD to CAD and control groups.
Conclusions:
- The study successfully identified a specific signature of circulating miRNAs in patients with CAAD.
- These miRNA profiles differ significantly from those in patients with CAD and healthy individuals.
- The findings suggest that circulating miRNAs could serve as potential biomarkers for CAAD.
Abstract:
To understand the mechanism underlying coronary artery abnormal dilatation (CAAD), the present study identified and compared the expression of circulating microRNAs (miRNAs) in three groups of patients. Group 1 included 20 patients with CAAD, Group 2 included 20 patients with angiographically confirmed coronary artery disease (CAD), and Group 3 included 20 patients with normal coronary arteries (control). miRNAs were isolated from plasma samples and were profiled using PCR arrays and miRCURY LNA Serum/Plasma Focus PCR Panels. The present study demonstrated that the plasma miRNA levels were significantly different in Group 1 compared with in Group 2 and Group 3 (fold change >2 and P<0.05). The comparison of Group 1 with Group 3 identified 21 significantly upregulated and two downregulated miRNAs in patients with CAAD compared with in the control group. Moreover, six upregulated and two downregulated miRNAs were identified in patients with CAD compared with in the controls. The third comparison revealed four upregulated and three downregulated miRNAs in Group 1, when compared with patients with CAD. In conclusion, the present study identified a specific signature of plasma miRNAs, which were upregulated and downregulated in patients with CAAD compared with in patients with CAD and control individuals.
